The National Institute of Allergies and Infectious Diseases is leading COVID-19 clinical trial efforts through a large-scale network, called the COVID-19 Prevention Network (CoVPN). Dr. Jim Kublin, the executive director of operations program for CoVPN, shares more about this government-funded clinical trials network for COVID-19, the importance of diversity in research, and how tech is rapidly advancing medical discoveries.
HealthCast
Season 2
Episode 1
23m listen
Ensuring Participant Diversity in COVID-19 Vaccine Trials
Share
Modern technology has the power to overcome clinical trial participation challenges.
-
Dr. Jim Kublin Executive Director of Operation Programs CoVPN
Related Content
-
Army Launches Joint Innovation Outpost to Accelerate Battlefield Capabilities
At Fort Bragg, the XVIII Airborne Corps’ Joint Innovation Outpost connects soldiers, engineers and industry to accelerate battlefield capability development.
23m listen -
Federal Courts Use GIS to Improve Security, Visitor Experience
The Administrative Office of the Courts is using geospatial intelligence systems data to integrate security systems, enhance safety and improve the visitor experience.
13m listen -
AI Decision Support System Aims to Improve Battlefield Triage
APPRAISE helps combat medics identify hemorrhage risk earlier and make faster triage and evacuation decisions.
7m watch -
VA Deputy Secretary on Resuming EHR Rollout
VA resumed rollout of its EHRM program this weekend after a three-year pause, and Paul Lawrence discusses early feedback and lessons learned.
15m watch
